LeMaitre Vascular, Inc. (NASDAQ:LMAT) Receives $95.25 Consensus PT from Analysts

LeMaitre Vascular, Inc. (NASDAQ:LMAT) has earned an average rating of “Moderate Buy” from the nine research firms that are currently covering the company, MarketBeat.com reports. Four equities research analysts have rated the stock with a hold recommendation, four have issued a buy recommendation and one has given a strong buy recommendation to the company. The average 1 year target price among brokerages that have issued a report on the stock in the last year is $95.25.

A number of brokerages recently commented on LMAT. StockNews.com lowered LeMaitre Vascular from a “buy” rating to a “hold” rating in a research note on Friday, December 13th. Oppenheimer downgraded shares of LeMaitre Vascular from an “outperform” rating to a “market perform” rating in a report on Friday, February 28th. Wells Fargo & Company began coverage on shares of LeMaitre Vascular in a research note on Thursday, February 13th. They issued an “equal weight” rating and a $95.00 target price on the stock. Barrington Research downgraded LeMaitre Vascular from an “outperform” rating to a “market perform” rating in a report on Friday, February 28th. Finally, Lake Street Capital increased their target price on LeMaitre Vascular from $105.00 to $110.00 and gave the stock a “buy” rating in a report on Friday, February 28th.

LeMaitre Vascular Price Performance

NASDAQ:LMAT opened at $79.78 on Wednesday. LeMaitre Vascular has a one year low of $62.39 and a one year high of $109.58. The company has a fifty day moving average price of $91.62 and a 200 day moving average price of $94.22. The stock has a market cap of $1.80 billion, a P/E ratio of 43.60, a PEG ratio of 2.22 and a beta of 0.89.

LeMaitre Vascular (NASDAQ:LMAT) last released its earnings results on Thursday, February 27th. The medical instruments supplier reported $0.49 earnings per share for the quarter, meeting the consensus estimate of $0.49. LeMaitre Vascular had a net margin of 19.40% and a return on equity of 13.15%. The business had revenue of $55.81 million during the quarter, compared to analysts’ expectations of $55.99 million. As a group, equities research analysts anticipate that LeMaitre Vascular will post 1.94 EPS for the current year.

LeMaitre Vascular Increases Dividend

The company also recently declared a quarterly dividend, which was paid on Thursday, March 27th. Stockholders of record on Thursday, March 13th were given a dividend of $0.20 per share. This represents a $0.80 dividend on an annualized basis and a dividend yield of 1.00%. This is a boost from LeMaitre Vascular’s previous quarterly dividend of $0.16. The ex-dividend date was Thursday, March 13th. LeMaitre Vascular’s dividend payout ratio (DPR) is currently 41.24%.

Insider Activity

In other news, insider Trent G. Kamke sold 2,009 shares of LeMaitre Vascular stock in a transaction that occurred on Wednesday, March 12th. The shares were sold at an average price of $82.12, for a total value of $164,979.08. Following the sale, the insider now directly owns 5,564 shares in the company, valued at $456,915.68. This trade represents a 26.53 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 10.79% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On LeMaitre Vascular

A number of institutional investors have recently added to or reduced their stakes in LMAT. Smartleaf Asset Management LLC increased its holdings in shares of LeMaitre Vascular by 234.4% during the fourth quarter. Smartleaf Asset Management LLC now owns 418 shares of the medical instruments supplier’s stock worth $39,000 after purchasing an additional 293 shares during the period. CBIZ Investment Advisory Services LLC grew its stake in LeMaitre Vascular by 38.5% during the fourth quarter. CBIZ Investment Advisory Services LLC now owns 421 shares of the medical instruments supplier’s stock worth $39,000 after buying an additional 117 shares in the last quarter. KBC Group NV increased its holdings in LeMaitre Vascular by 58.4% in the 4th quarter. KBC Group NV now owns 1,112 shares of the medical instruments supplier’s stock valued at $102,000 after buying an additional 410 shares during the period. Huntington National Bank raised its position in shares of LeMaitre Vascular by 64.9% in the 4th quarter. Huntington National Bank now owns 1,156 shares of the medical instruments supplier’s stock valued at $107,000 after buying an additional 455 shares in the last quarter. Finally, Empowered Funds LLC bought a new stake in shares of LeMaitre Vascular during the 4th quarter worth approximately $150,000. 84.64% of the stock is currently owned by institutional investors and hedge funds.

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.